2026-08-10
Q3 2026 · in 49d
- Est. Revenue
- $0
- Est. EPS
- -$0.08
Earnings Calendar🇺🇸 United States
ANAVEX LIFE SCIENCES CORP. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 82 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
Est. = analyst consensus (Finnhub)
Future earnings · next 8 quarters
| Report date | Fiscal Q | Est. Revenue | Est. EPS | Call Time | In |
|---|---|---|---|---|---|
| 2026-08-10 | Q3 2026 | $0 | -$0.08 | — | in 49d |
| 2026-11-23 | Q4 2026 | $0 | -$0.11 | AMC | in 154d |
| 2027-02-08 | Q1 2027 | — | -$0.12 | — | in 231d |
Forward dates from Finnhub. Smaller filers and foreign listings sometimes publish dates only ~6 weeks before the report — check back closer to the next anticipated quarter.
Last earnings · FY2025 (Q4)
Revenue
$1.08M
-$315K -22.6% YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEarnings Surprise
YoY % change · proxy for analyst surprise
-22.60%(2025-12 vs 2025-09)
Loading chart data, please wait.
EPS history · last 10 fiscal years
diluted, GAAP, annualEPS History
Diluted, GAAP, annual
-5.55%(FY25 vs FY24)
Loading chart data, please wait.
Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock-split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
AVXL Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyAVXL Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics